• Edgewise Therapeutics Inc EWTX.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of twelve analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -48 cents to -38 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Edgewise Therapeutics Inc's reported EPS for the quarter was a loss of 34 cents​.

• The company reported a quarterly loss of $36.12 million.

• Edgewise Therapeutics Inc shares had risen by 3.1% this quarter and lost 49.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Edgewise Therapeutics Inc is $46.00, about 70.6% above its last closing price of $13.52

This summary was machine generated from LSEG data August 7 at 05:18 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)